Patents
Literature
3 results about "Octreotide" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Octreotide is used to treat severe watery diarrhea and sudden reddening of the face and neck caused by certain types of tumors (e.g., carcinoid tumors, vasoactive intestinal peptide tumors) that are found usually in the intestines and pancreas.
Combinations of imaging agent conjugates and uses thereof
The present invention provides a combination of two or more imaging agent conjugates comprising an imaging agent conjugated to a targeting ligand, wherein the imaging agent comprises one or more of: ZW800-1, ZW830-1, ZW700-1-Forte, ZW-DOTA, ZW-PyC3A, ZW-Macropa, ZW-Porphyrin, ZW-NOTA, and ZW-Deferoxamine; and the targeting ligand comprises one or more of: cRGD, dPSMA-617 or KUE, FAP, Bombesin Receptor Binding Vector, or Octreotide Binding Vector, or one or more of the peptides selected from SEQ ID Nos: 1 to 4.
Owner:KURADALE SURGICAL INNOVATIONS
Combinations of imaging agent conjugates and application thereof
The present invention provides a combination of two or more imaging agent conjugates comprising an imaging agent conjugated to a targeting ligand, wherein the imaging agent comprises one or more of ZW800-1, ZW830-1, ZW700-1-Forte, ZW-DOTA, ZW-PyC3A, ZW-Macropa, ZW-porphyrin, ZW-NOTA, and ZW-Deferoxamine; and the targeting ligand comprises one or more of a cRGD, a dPSMA-617 or a KUE, a FAP, a bombesin receptor binding vector, or a octreotide binding vector, or one or more of peptides selected from SEQ ID No: 1-4.
Owner:CURADEL SURGICAL INNOVATIONS INC
Green solvent-based mixed-solvent strategy for the synthesis of peptide
The present invention relates to a mixed green solvent based process for the preparation of peptide. More specifically, the present invention relates to a process of the preparation of Octreotide using greener solvent. The process of present invention also focused on minimizing solvent consumption, especially DMF, trifluoroacetic acid (TFA) and ethers. The process of present invention also substitutes acetonitrile with methanol in the chromatographic purification steps. The process of present invention only addresses environmental concerns associated with DMF usage but also maintains the efficiency and effectiveness of the Octreotide synthesis process.
Owner:ENZENE BIOSCIENCES LTD